Back to News
Market Impact: 0.32
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Roche's (RHHBY) supplemental biologics license application for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease received FDA Priority Review. The FDA decision date is Jan. 10, 2027, accelerating the review timeline and creating a potential new indication catalyst for the drug.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- How This County Made the Data Center Boom Pay Off
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The Great Divergence: North American Banking at the Crossroads of Monetary Policy and Agentic AI (Q4 2025 Bank Earnings)
- AI for M&A Target Screening: From Universe to Deal File